Please login to the form below
ipilimumab
This page shows the latest ipilimumab news and features for those working in and with pharma, biotech and healthcare.
BMS eyes approval for second Opdivo combo in kidney cancer
Opdivo is already approved in combination with Yervoy (ipilimumab) as an initial treatment for advanced RCC patients, after the treatment showed an ability to improve survival compared to Sutent. ... However, it has been facing competition from Merck
Latest news
-
BMS suspends new clinical trials as COVID-19 cases rise in US
Both of those are also under review in Europe. Following after is an FDA review of checkpoint inhibitor combination Opdivo (nivolumab) and Yervoy (ipilimumab) in first-line non-small cell lung
-
BMS scores first oesophageal cancer nod for Opdivo in Japan
It has also gained a number of approvals as of late in combination with CTLA4 blocker Yervoy (ipilimumab), as BMS continues to strengthen its Opdivo franchise against a myriad of competitors.
-
FDA sets June decision date for Tecentriq monotherapy in NSCLC
Bristol-Myers Squibb’s own PD-1 inhibitor Opdivo(nivolumab) is currently under review with the FDA, in combination with low-dose CTLA4 inhibitor Yervoy (ipilimumab) in previously-untreated NSCLC patients
-
BMS unveils long-term results for Opdivo in kidney cancer
BMS also reported updated results from its CheckMate-214 trial, which evaluated Opdivo in combination with Yervoy (ipilimumab).
-
NICE turns down Keytruda/Inlyta combo for kidney cancer
and Yervoy (ipilimumab) thanks to the Checkmate-214 study.
More from news
Approximately 8 fully matching, plus 171 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better long-term survival than the Keytruda/chemotherapy combination which is driving the growth
-
Combined immunotherapies – potential and pitfalls
This contrasts with the approved ipilimumab-nivolumab combination therapy, which costs $256, 000 a year, according to the researchers.
-
Cancer immunotherapy: What's on the horizon?
drug Yervoy (ipilimumab) in an early-stage trial.
-
Pharma deals in February 2015
As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
-
Pharma deals during July 2014
Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is FDA approved for late-stage melanoma.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
CytomX appoints Rachel Humphrey chief medical officer
drug Yervoy (ipilimumab).
-
Jonathan Dickinson joins Ariad from BMS
population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
Immunotherapy in oncology
This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II ... This led to a changing of the primary
-
ASCO 2015: What you missed in Chicago
In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- New medical communications agency BOLDSCIENCE launches
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA approves Roche’s Actemra COVID-19 trial
- Shionogi's Gram-negative antibiotic launches in the UK
- Improve clinical trials through patient journey mapping
- Live Webinar: Medical Modeling in Virtual Reality
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
